Comparison of the efficacy and bioequivalence of two oral formulations of tiludronate in the treatment of Paget's disease of bone

Clinical Therapeutics

Volumn 19, Issue 5, 1997, Pages 963-974

  Morales Piga, Antonio ^a   Del Pino, Javier ^b   Rapado, Aurelio ^c   Diaz Curiel, Manuel ^c   Pallares, Montserrat ^d   Gonzalez Macias, Jesus ^e  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Efficacy; Paget's disease; Pharmacokinetics; Tiludronate

Indexed keywords

TILUDRONIC ACID;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PAGET BONE DISEASE;

EID: 0030665638     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80049-5     Document Type: Article

References (41)

1. Audran M, Clochon P, Ethgen D, et al. Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonate. Clin Rheumatol. 1989;8:71-79.
2. Reginster JY, Colson F, Morlock G, et al. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double blind, multiple-dosage, placebo-controlled study. Arthritis Rheum. 1992; 35:967-974.
3. Reginster JY, Lecart MP, Deroisy R, et al. Paget's disease of bone treated with a five day course of oral tiludronate. Ann Rheum Dis. 1993;98(Suppl 2A):525-555.
4. Reginster JY, Treves R, Rénier JC. et al. Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone. J Bone Miner Res. 1994;9:615-619.
5. McClung MR, Tou CKP, Goldstein NH, Picot C. Tiludronate therapy for Paget's disease of bone. Bone. 1995;17(Suppl): 493S-496S.
6. Roux C. The methodology of clinical trials of oral tiludronate in Paget's disease of bone. Bone. 1995;17(Suppl):497-499.
7. Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum. 1995;38:851-858.
8. Reginster JY, Deroisy R, Lecart MP, Franchimont P. (Chloro-4-phenyl) thiomethylene bisphosphonate in Paget's disease. Acta Belg Med Phys. 1989;12:47-52.
9. Reginster JY. Oral tiludronate: Pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone. 1992;13:351-354.
10. Audran M, Rénier JC, Clochon P, et al. Treatment of Paget's disease of bone with SR41319B, a new diphosphonate (preliminary results). Clin Rheumatol. 1989;8: 71-79.
11. Lecart MP, Jeugmans-Huynen AM, Albert A, et al. Biological and clinical effects of a new bisphosphonate (chloro-4-phenyl) thiomethylene bisphosphonate in Paget's disease. Rev Med Liege. 1988;43: 799-806.
12. Reginster JY, Jeugmans-Huynen AM, Albert A, et al. Biological and clinical assessment of a new bisphosphonate, (chloro-4-phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone. Bone. 1988;9:349-354.
13. Nagant de Deuxchaisnes C, Devogelaer JP, Cornet F, et al. The effect of the (4-chloro phenyl) thiomethylene disodium bisphosphonate or SR41319B in Paget's disease of bone: A biological study. Calcif Tissue Int. 1987;41(Suppl 2): 180. Abstract.
14. Nagant de Deuxchaisnes C, Devogelaer JP, Malghem J, et al. The effect of the (4-chloro phenyl) thiomethylene disodium bisphosphonate or SR41319B in Paget's disease of bone: A radiologic study. Calcif Tissue Int. 1987;41(Suppl 2):179. Abstract.
15. Cook D. A history of bioavailability testing in the food and drug directorate. Rev Can Biol. 1973;32(Suppl): 157-162.
16. Recker RR, Saville PD. Intestinal absorption of disodium ethane-1-hydroxyl-1,1-diphosphonate (disodium etidronate) using a deconvolution technique. Toxicol Appl Pharmacol. 1973;24:580-589.
17. Yakatan GL, Poynor WJ, Talbert RL, et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther. 1982;31:402-410.
18. Fogelman I, Smith L, Mazess R, et al. Absorption of oral bisphosphonate in normal subjects. Clin Endocrinol. 1986;24:57-62.
19. Sansom LN, Necciari J, Thiercelin JF. Human pharmacokinetics of tiludronate. Bone. 1995;17(Suppl):479S-483S.
20. Boulenc X, Marti E, Joyeux H, et al. Importance of the paracellular pathway for the transport of a new bisphosphonate using the human Caco-2 monolayers model. Pharmacol Biochem. 1993;46:1591-1600.
21. Twiss IM, DeWater R, DenHartigh J, et al. Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci. 1994;83:699-703.
22. Armstrong WM, Garcia-Diaz JF. Electrical phenomena and ion transport in the small intestine. In: Csaky TZ, ed. Handbook of Experimental Pharmacology. Vol. 70(I). New York: Springer; 1984:309-380.
23. Schultz SG, Frizzell RA, Nellons HN, Ion transport by mammalian small intestine. Annu Rev Physiol. 1974;36:51-91.
24. Fleisch H. Bisphosphonates in Bone Diseases. From the Laboratory to the Patient. In: Fleisch H, ed. Pharmacokinetics. 2nd ed. London: The Parthenon Publishing Group.
25. Hyldstrup L, Flesch G, Hauffe SA. Pharmacokinetic evaluation of pamidronate after oral administration: A study on dose proportionality, absolute bioavailability, and effect of repeated administration. Calcif Tissue Int. 1993;53:297-300.
26. Gertz BJ, Holland SD, Kline WF, et al. Clinical pharmacology of alendronate sodium. Osteoporosis Int. 1993;3(Suppl 3):513-516.
27. Daley-Yates PT, Dodwell DJ, Pongchaidecha M, et al. The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int. 1991;49:433-435.
28. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Oilman AG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: Pergamon Press Inc; 1996:3-27.
29. Westlake WJ. Statistical aspects of comparative bioavailability trials. Biometrics. 1979;35:273-280.
30. Bois FY, Tozer TN, Hauck WW, et al. Bioequivalence: Performance of several measures of rate of absorption. Pharm Res. 1994;11:906-914.
31. Jacob F, Debry G, Lascombes F, Necciari J. Tiludronate: Pharmacokinetic dose proportionality after intravenous administration. Absolute bioavailability in healthy volunteers. J Bone Miner Res. 1996;11: S347. Abstract.
32. Kanis JA. Pathophysiology and Treatment of Paget's Disease of Bone. London: Martin Dunitz; 1991:56-72.
33. Khairi MRA, Wellman HN, Robb JA, Johnston CC. Paget's disease of bone (osteitis deformans): Symptomatic lesions and bone scan. Ann Intern Med. 1973; 79:348-351.
34. Khairi MRA, Robb JA, Wellman HN, Johnston CC. Radiographs and scans in diagnosing symptomatic lesions of Paget's disease of bone (osteitis deformans). Geriatrics. 1974;29:49-54.
35. Franck WA, Bress NM, Singer FR, Krane SM. Rheumatic manifestation of Paget's disease of bone. Am J Med. 1974;56: 592-603.
36. Meunier PJ, Saison C, Mathieu L, et al. Skeletal distribution of Paget's disease. Clin Orthop. 1987;217:37-44.
37. Huskisson EC. Measurement of pain. Lancet. 1974;2:1127-1131.
38. Nordin BEC, Horsman A, Aaron J. Diagnostic procedures. In: Nordin BEC, ed. Calcium, Phosphate and Magnesium: Metabolism, Clinical Physiology and Diagnostic Procedures. New York: Churchill Livingstone; 1976:469-524.
39. Pels JP, Guyonnet J, Berger Y, Cautreels W. Determination of SR41319, a new bisphosphonate in biological fluids by HPLC. J Chromatogr. 1988;430:73-79.
40. Walton RJ, Preston CJ, Bartlett M, et al. Biochemical measurements in Paget's disease of bone. Distribution and correlations. Eur J Clin Invest. 1977;7:37-39.
41. Kanis JA, McCloskey EV. The use of clodronate in disorders of calcium and skeletal metabolism. In: Kanis JA. ed. Calcium Metabolism. Progress and Basic Clinical Pharmacology. Vol. 4. Basel: Karger; 1990: 89-136.